Alaunos Therapeutics (TCRT) Return on Equity (2016 - 2025)
Historic Return on Equity for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to 1.26%.
- Alaunos Therapeutics' Return on Equity rose 24400.0% to 1.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.26%, marking a year-over-year increase of 24400.0%. This contributed to the annual value of 1.14% for FY2024, which is 4700.0% up from last year.
- According to the latest figures from Q3 2025, Alaunos Therapeutics' Return on Equity is 1.26%, which was up 24400.0% from 1.71% recorded in Q2 2025.
- Alaunos Therapeutics' Return on Equity's 5-year high stood at 0.54% during Q1 2021, with a 5-year trough of 4.94% in Q1 2024.
- Over the past 5 years, Alaunos Therapeutics' median Return on Equity value was 1.26% (recorded in 2025), while the average stood at 1.94%.
- Its Return on Equity has fluctuated over the past 5 years, first crashed by -37900bps in 2024, then skyrocketed by 28500bps in 2025.
- Over the past 5 years, Alaunos Therapeutics' Return on Equity (Quarter) stood at 0.9% in 2021, then dropped by -20bps to 1.08% in 2022, then crashed by -231bps to 3.59% in 2023, then soared by 44bps to 2.0% in 2024, then surged by 37bps to 1.26% in 2025.
- Its Return on Equity stands at 1.26% for Q3 2025, versus 1.71% for Q2 2025 and 2.64% for Q1 2025.